The treatment of malignant tumors is still a worldwide problem. Currently, the main treatment methods include surgery, radiotherapy, chemotherapy, immunotherapy and targeted therapy. “Tumor apoptosis” therapy is a genetic engineering therapy technology that starts the process of tumor apoptosis by secreting and expressing relevant bioactive peptides in vivo to target the treatment of malignant tumors, which has brought a revolutionary breakthrough in tumor treatment and achieved definite efficacy in some patients who have given up on traditional treatment. The results of practical use studies of the combination of multiple secreted peptides with tumor-modulating effects have shown significant effects on malignant tumor treatment. 1.Therapeutic mechanism. Apoptosis refers to the autonomous and orderly cell death controlled by genes in order to maintain the stability of the internal environment. Apoptosis is different from cell necrosis. Apoptosis is not a passive process, but an active process, which is a kind of death process for better adaptation to the survival environment. Apoptosis is a fundamental biological phenomenon of cells and plays a necessary role in the removal of unwanted or abnormal cells in multicellular organisms. It plays an important role in the evolution of organisms, the stability of the internal environment, and the development of several systems. Apoptosis is not only a specific type of cell death, but also has important biological significance and complex molecular biological mechanisms. The proliferation and senescence of normal human cells are strictly controlled, dividing approximately 56-60 times. Apoptosis is a process strictly controlled by multiple genes, and although the exact mechanism of the apoptotic process is not fully understood so far, the disruption of the apoptotic process may be directly or indirectly related to the occurrence of many diseases. For example, tumors, autoimmune diseases, etc. Malignant tumor patients are different from normal human beings in that their cells can divide indefinitely without control and have the ability to spread, becoming “immortal” cells. Under normal circumstances, the body will produce various bioactive peptides to regulate the abnormal cells to make them return to normal, or directly apoptosis to remove the abnormal cells to protect the body. However, in tumor patients, this ability is often absent or decreased. The apoptotic mechanism cannot act on tumor cells. Active peptide is is the main active substance that regulates the nucleus of the cell and consists of amino acids, which are the basic functional units of proteins, and there is a wide variety of peptides that can regulate almost all functions of all cells. Different active peptides have specificity of action sites and precise localization. According to the above characteristics of active peptide, it has been used in the current scientific research results of bioactive peptide have entered the application stage and achieved remarkable efficacy. For active peptide therapy, there are many insurmountable technical barriers and cost barriers that cannot be applied to the actual clinical treatment if the traditional exogenous input route of in vitro synthesis and then input into the body is used. Different from the exogenous input method, the in vivo secretory expression technology is the difficult point to realize the application and production of peptide drugs, which is the key to improve the efficacy of peptide drugs, and has the originality and advancement in domestic and international. This method is to introduce bioactive functional peptide genes into human cells, so that the host cells can produce a large amount of tumor-killing bioactive peptide – tumor-specific apoptotic peptide, and enter the target cells through various secretion mechanisms to play the role of systemic tumor cell killing (as shown in Figure 1). By this method, the patient can produce the active peptide by itself. The in vivo secretory expression technology has obvious advantages in safety and efficacy, and the effect of “teaching a man to fish is better than teaching a man to fish”. This unique therapeutic mechanism provides a new treatment option for many end-stage tumor patients for whom traditional treatment is ineffective. Flow chart of in vivo secretion expression technology 2. Treatment targets. This technology can be used for patients with solid tumors whose general condition is not very poor, or patients who cannot be treated with chemotherapy after surgery or those who are intolerant to chemotherapy, and the specific condition needs to be judged by doctors. 3.Effectiveness. Generally, the general condition of the body can be significantly improved in the first week after the treatment, and the tumor-related pressure symptoms can be reduced. With the prolongation of treatment time, imaging changes can also be observed, and the survival period of some patients is prolonged, and some patients even achieve the result of long-term survival with tumor. 4.Treatment route. Injection therapy is mainly used. Except for the slight pain caused by injection, the treatment itself will not produce other pain. (1) Local tumor injection: mainly for large solid tumors, with rapid onset of action. (2) Intravenous drip: to increase the production of secreted peptide and maintain for a long time. (3) Intramuscular injection: maintain the effect for a long time. 5.Treatment course. Shock treatment: in the first month, 30 or 60 groups of secretory peptide are used (divided into regular treatment and maintenance treatment, the number of groups is determined by the doctor according to the size and scope of tumor); consolidation treatment: in the second month, according to the effect of shock treatment, intramuscular injection is recommended (1 group/day, 30 days of treatment; maintenance treatment: according to the effect of consolidation treatment and cell metabolic cycle, personalized formulation. Tumors are characterized by constant variability and their targets are changing. For this reason, we designed a series of short peptide drugs for treating different tumors and different stages of tumors based on the knowledge of modern tumor molecular biology for common targets and variant targets. When using the specific target short peptide treatment, although it can treat the tumor and see the efficacy, but still can not guarantee the tumor does not recur and metastasis. 6.The cost of treatment. In order to show the efficacy as soon as possible, the highest cost of impact treatment period, with the emergence of efficacy, the cost of subsequent treatment, there will be a significant reduction of such a law, the specific cost, need to be combined with the specific program developed by the doctor to determine. 7.Safety evaluation. First, the adeno-associated virus vector used in this technology is currently the safest internationally recognized vector, widely used in in vitro gene therapy research, foreign countries have adeno-associated virus as the vector of gene drugs in doing drug clinical research. Secondly, the biologically active peptide produced is derived from normal human protein, which has targeting effect on tumor cells with precise target point and no effect on normal cells, and can be degraded naturally in the body without adverse reactions. 8.Adverse reaction. In the process of treatment, some patients may have fever reaction, and doctors can carry out symptomatic treatment. Compared with traditional radiotherapy, the adverse reactions of this technology can be said to be minimal.